南宫NG·28(中国)相信品牌力量

Shenzhen, China – From April 14 to April 16, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Sixth Pangu Aortic Disease Forum held in Shenzhen, Guangdong Province. The forum, chaired by Professor Lizhong Sun of Beijing Anzhen Hospital of Capital Medical University, invited over 100 aortic specialists to have in-depth discussion on the new technology, new achievement, and new development of the aortic surgery.

The forum covered five topics including the surgical technique of type A dissection aortic root lesion, the surgical technique of type A dissection aortic arch lesion, the treatment strategy and method of aortic intramural hematoma, the surgical treatment strategy and method of descending aorta aneurysm, and intractable/complex/rare aortic disease cases. Director Hao Lai of Shanghai Fudan University of Zhongshan Hospital made a presentation on "the application of Fontus™ Branched Surgical Stent Graft System in treating TAAD arch." He said, currently open surgery is the principal treatment of aortic arch and dissection. Fontus™ Branched Surgical Stent Graft System in-house developed by MicroPort® Endovascular reduces anastomosis in the LSA and moves the arch anastomosis forward, which makes the operation much easier. At the same time, the product is equipped with better material. On one side, compared to the previous generation that is made of cobalt-chromium alloy, it adopts nitinol which largely enhances the roundness of true lumen, improves the rate of the false lumen closure, lowers anastomosis bleeding, and makes the suture of arch anastomosis more simple and safe. On the other side, the proximal collagen coated graft is coated synthetic vascular graft, which further reduces intraoperative blood loss.

Director Ren Wang of Fujian Provincial Hospital delivered a speech on "the branches reconstruction technique of aortic arch." He said, total aortic arch replacement + elephant trunk procedure is the principal method to treat aortic arch, but for extracorporeal circulation in high-risk patients, total aortic arch replacement by hybrid technique is more suitable for them, and most descending aorta lesion can be treated with interventional technique. He highlighted the necessity of restoring left subclavian artery blood supply in thoracic endovascular aortic repair ("TEVAR"), and under that condition, MicroPort® Endovascular's Castor™ Branched Aortic Stent-Graft System ("Castor™") is a more rational and safer option. Meanwhile, Professor Wenhui Wu of Beijing Anzhen Hospital of Capital Medical University shared about the clinical treatment of aortic intramural hematoma. He pointed out narrow access vessel is a universal problem found in TEVAR, which requires lower profile delivery system. Hercules™ Low-Profile Thoracic Stent-Graft System, in-house developed by MicroPort® Endovascular, is designed with outer diameter of delivery sheath 4F lower than competitive products, which reduces the damage to blood vessel and suits for cases with narrow access vessels, vascular calcification and tortuous vascular.

Established in October, 2009, Pangu Aortic Disease Forum is an influential academic meeting in the aortic disease field, hosted by Cardiovascular Surgical Technique and Engineering Branch of China Medicinal Biotech Association and the Aortic Special Committee of Chinese Association of Cardiovascular Surgeons. MicroPort® Endovascular primarily focuses on R&D, and manufacturing support of the interventional medical devices, including AAA/TAA stent graft systems, surgical stent graft system, aortic balloon dilation catheter and peripheral vascular stents/balloons. It will continue to strive for innovation and product diversification, to help promote the development of China's aotic surgical technique.